Wei Chang Zhou
Directeur/Membre du Conseil chez WUXI BIOLOGICS (CAYMAN) INC.
Fortune : 714 532 $ au 30/06/2024
Postes actifs de Wei Chang Zhou
Sociétés | Poste | Début | Fin |
---|---|---|---|
WUXI BIOLOGICS (CAYMAN) INC. | Directeur/Membre du Conseil | 01/05/2016 | - |
Directeur Technique/Scientifique/R&D | 01/11/2016 | 31/03/2024 | |
WUXI XDC CAYMAN INC. | Directeur/Membre du Conseil | 01/12/2020 | - |
Historique de carrière de Wei Chang Zhou
Anciens postes connus de Wei Chang Zhou
Sociétés | Poste | Début | Fin |
---|---|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/03/2008 | 01/12/2012 |
PDL BIOPHARMA, INC. | Directeur/Membre du Conseil | 01/10/2002 | 01/02/2008 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/05/1994 | 01/10/2002 |
Formation de Wei Chang Zhou
Jiangxi University of Science & Technology | Undergraduate Degree |
University of Hannover | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 4 |
Chine | 3 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
WUXI BIOLOGICS (CAYMAN) INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
WUXI XDC CAYMAN INC. | Commercial Services |
Entreprise privées | 2 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Bourse
- Insiders
- Wei Chang Zhou
- Expérience